Get notified of page updates
Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204)
Glossary on
off
About the Study
This study is no longer enrolling patients.
This study is for people with advanced or endometrial cancer that has progressed on or after platinum-based chemotherapy. Participants will receive retifanlimab (a type of ) alone or in combination with other immunotherapies or targeted therapies.
This Study is Open To:
This study is no longer enrolling patients.
This Study is NOT Open To:
This study is no longer enrolling patients.